Nanoscope Therapeutics has completed enrollment in a phase 2b clinical trial investigating the efficacy and safety of MCO-010 in patients with retinitis pigmentosa, according to a press release.
Twenty-seven patients with severe vision loss due to advanced retinitis pigmentosa will receive an injection of MCO-010, “an ambient-light activatable multi-characteristic opsin optogenetic monotherapy,” or sham injection in the randomized, double-masked, sham-controlled, multicenter trial.
In a phase 1/2a study in 11 patients, MCO-010 was well tolerated and improved quality of life, “consistent